新型结合剂用于移植患者早期术后高血症:单中心体验
Alesa Campbell1, Weirui Xiao2, Enver Akalin3
1Montefiore Medical Center Department of Pharmacy, Center for Transplantation, Bronx, NY, USA.
Transplantation proceedings
|August 22, 2024
概括
新型结合剂如帕蒂罗默和环酸盐 (SZ-9) 似乎是早期移植后高血症管理的安全药物. 它们可能有助于降低,但不会减少延迟移植功能患者的透析需求.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 移植免疫学 移植免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 超血是移植后的一个常见并发症.
- 移植后高血症的有效管理对于移植的生存和患者的结果至关重要.
- 新型结合剂提供了潜在的治疗选择.
研究的目的:
- 评估新型结合剂的安全性和有效性,特别是帕特和环酸盐 (SZ-9),用于治疗移植后的早期术后高血症.
- 评估这些结合剂对移植功能和患者结局的影响.
主要方法:
- 一个回顾性,单中心队列研究包括2018年1月至2020年12月间移植的已故捐赠者接受者.
- 从移植后到出院时,追踪结合剂的使用情况,与其他药物相比,给药时间有所不同.
- 分析了患者数据,包括水平,移植功能和不良事件.
主要成果:
- 共有179名患者被研究;24人 (13%) 接受结合剂 (帕蒂罗默,SZ-9,或两者).
- 服用结合剂的患者的峰水平较高 (6.05比5.35mEq/L).
- 结合剂的使用与更高的转换到atovaquone和更高的延迟移植功能 (DGF) 发病率有关,但没有更多的透析治疗或增加胃肠道症状.
结论:
- 帕蒂罗默和SZ-9在移植后的早期阶段显示出安全性,因此需要在更大规模的前性试验中进一步调查.
- 虽然这些结合剂可能有助于减少,但它们似乎不会减少DGF患者透析的需要.
- 结合剂可以作为辅助工具来管理移植患者的高血清症.
相关概念视频
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
477
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
477
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
936
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
936
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:20Antiepileptic Drugs: Potassium Channel Activators
150
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
150
01:26Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545